Literature DB >> 31993862

Molecular detection of Epstein-Barr virus in different types of lymphoma.

Khawla Shaklawoon1, Nuria Altagazi2, Fairuz Altorjman2, Abdulfattah Alturki3, Mohamed Eltaweel4, Omar Alqawi5,6.   

Abstract

Epstein-Barr virus (EBV) is a member of the γ herpesvirus subfamily. It is widely spread, potentially oncogenic and has been studied in different human cancers such as gastric carcinoma, nasopharyngeal carcinoma and both Hodgkin's and non-Hodgkin's lymphomas. EBV replicates in the oral epithelium, and resting B lymphocytes trafficking through the pharynx develop a latent infection in which only EBV genes related to the B cell growth program are expressed: LMP1, -2a/b, BARTs, EBERs and EBNAs. EBNA1 binds a specific DNA sequence in the viral genome responsible for episome replication, segregation and persistence of the viral genome, and is involved in p53 degradation and oncogenesis. It is also involved in p53 degradation and oncogenesis. Since EBV infection is associated with the progression of malignancy in lymphoma, we used EBNA1-based PCR to determine the frequency of EBV infection in lymphoma specimens from patients with different types of lymphomas. Biopsies from lymphoma patients obtained from National Cancer Institute, Misurata and Tripoli Medical Centre (Libya) showed the presence of EBV in 31 of 40 cases (77%). EBV infection rates did not differ significantly between Hodgkin's lymphoma, and non-Hodgkin's lymphoma. The rates did not vary significantly between the sexes or age groups.

Entities:  

Keywords:  EBNA1; Epstein–Barr nuclear antigen-1; Epstein–Barr virus; Hodgkin’s lymphoma; Non-Hodgkin’s lymphoma

Mesh:

Substances:

Year:  2020        PMID: 31993862     DOI: 10.1007/s11033-020-05274-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  4 in total

1.  Direct Epstein-Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma.

Authors:  D van Baarle; E Hovenkamp; M J Kersten; M R Klein; F Miedema; M H van Oers
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

Review 2.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.

Authors:  Kenny I K Lei; Lisa Y S Chan; Wing-Yee Chan; Philip J Johnson; Y M Dennis Lo
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

Review 4.  The Epstein-Barr Virus EBNA1 Protein.

Authors:  Lori Frappier
Journal:  Scientifica (Cairo)       Date:  2012-12-19
  4 in total
  3 in total

1.  Detection of low-load Epstein-Barr virus in blood samples by enriched recombinase aided amplification assay.

Authors:  Jing-Yi Li; Xiao-Ping Chen; Yan-Qing Tie; Xiu-Li Sun; Rui-Qing Zhang; An-Na He; Ming-Zhu Nie; Guo-Hao Fan; Feng-Yu Li; Feng-Yu Tian; Xin-Xin Shen; Zhi-Shan Feng; Xue-Jun Ma
Journal:  AMB Express       Date:  2022-06-11       Impact factor: 4.126

2.  Variable Expression of Notch1 and Pax5 in Classical Hodgkin Lymphoma and Infection with Epstein-Barr in Pediatric Patients.

Authors:  Icela Palma-Lara; Ana Elena Sánchez-Aldana; Elva Jiménez-Hernández; Octavio Martínez-Villegas; Juan Carlos Núñez-Enríquez; Juan Manuel Mejía-Aranguré; Sara A Ochoa; Juan Xicohtencatl-Cortes; Ariadnna Cruz-Córdova; Sergio Zavala-Vega; Mariana García-Jiménez; Alejandra Contreras-Ramos; José Refugio Torres-Nava; Guillermo Mora-Ramiro; José Arellano-Galindo
Journal:  Microorganisms       Date:  2020-06-26

3.  Activation of MEK1/2/Nrf-2 Signaling Pathway by Epstein-Barr Virus-Latent Membrane Protein 1 Enhances Autophagy and Cisplatin Resistance in T-Cell Lymphoma.

Authors:  Xintao Jia; Qiuyu He; Mei Zeng; Yuhua Chen; Yan Liu
Journal:  Anal Cell Pathol (Amst)       Date:  2021-06-18       Impact factor: 2.916

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.